- 24 h
- letzte 200 News
| Zeit | Aktuelle Nachrichten | ||
|---|---|---|---|
| 21.07. | Halozyme and Incyte sign licence agreement for INCA033989 formulations | ||
| 20.07. | Novartis and Takeda drugs gain rare blood cancer routine use on NHS | ||
| 20.07. | Samsung Biologics to acquire PolyPeptide in $1.81bn cash deal | ||
| 20.07. | UK biotech financing continues recovery trajectory on five-year Q2 high | ||
| 20.07. | Aptar unveils framework for injectable drug delivery systems | ||
| 17.07. | Bayer's heart failure drug bound for NHS on NICE recommendation | ||
| 17.07. | FDA grants traditional approval to Novartis' Fabhalta for IgAN | ||
| 17.07. | MSD wins FDA approval for cholesterol pill to help plug Keytruda void | ||
| 17.07. | JCVI issues recommendation on adolescent MenB vaccination in UK | ||
| 16.07. | UK commits to pharma IP protection in Swiss trade deal | ||
| 16.07. | Novo secures European approval for oral Wegovy to extend lead over Lilly | ||
| 16.07. | Lilly enters psychedelic realm through $2.8bn AtaiBeckley takeover | ||
| 16.07. | Big pharma-backed AdvanCell pockets $315m to progress RLT to Phase III | ||
| 16.07. | Telix opens radiopharmaceutical facility in Australia for cancer treatment | ||
| 16.07. | Harbour BioMed and Kelun-Biotech receive China IND approval for asthma therapy | ||
| 15.07. | J&J raises FY26 outlook following positive Q2 | ||
| 15.07. | Women's health attracted record equity in 2025 as companies share capital | ||
| 15.07. | AAIC26: The role of biomarkers in primary care and early diagnostics | ||
| 15.07. | FDA grants priority review to Roche's Gazyva/Gazyvaro for pMN | ||
| 15.07. | Innovent licenses IBI355 rights to Spero for up to $1.1bn | ||
| 14.07. | AstraZeneca pays up to $1.5bn to license Dizal Pharma's lung cancer drug | ||
| 14.07. | Novartis and Chai Discovery collaborate on antibody identification | ||
| 14.07. | Cellares and Sonoma partner to automate cell therapy manufacturing | ||
| 13.07. | Germany approves healthcare costs overhaul despite significant pharma opposition | ||
| 13.07. | "Hub-and-spoke" drug manufacturing set to benefit from new FDA rule |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.